Home › Compound Library › Empagliflozin (Jardiance)

Empagliflozin (Jardiance)

SGLT2 Inhibitorprescriptionoral · inferred

Sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule, causing glycosuria (~70g glucose/day excreted). Reduces HbA1c, blood pressure (osmotic diuresis), and body weight (~2-3 kg). Landmark EMPA-REG trial showed 38% reduction in cardiovascular death — now first-line for heart failure with or without diabetes. Also approved for CKD. UTI and genital mycotic infection risk. Rare DKA risk even with normal glucose.

Projected serum levels — 10 mg, once daily

Empagliflozin (Jardiance)
Empagliflozin (Jardiance) modeled serum levels, 10 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Empagliflozin (Jardiance) modeled serum levels with a loading dose of 13.6 mg, then 10 mg once daily The first dose is larger so levels approach steady state faster. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 10 mg once daily (oral).

Loading schedule: 13.6 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 9.7 mg, trough ≈ 2.8 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
SGLT2 Inhibitor
Route modeled
Oral
Model confidence
inferred
Half-life
12 h
Common dose
10 mg
Suggested maximum
25 mg/day
Reference dose range
5–25 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.12 mg/L at 1.5 h

Documented interactions

  • moderate
    Apigenin + Empagliflozin (Jardiance) Transporter inhibition

    Apigenin inhibitor of BCRP may alter Empagliflozin (Jardiance) absorption / distribution

  • moderate
    Carvedilol (Coreg) + Empagliflozin (Jardiance) Transporter inhibition

    Carvedilol (Coreg) inhibitor of P-gp may alter Empagliflozin (Jardiance) absorption / distribution

  • moderate
    CBD (Cannabidiol) + Empagliflozin (Jardiance) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of UGT2B7 predicted to change Empagliflozin (Jardiance) AUC by ~1.36x

  • moderate
    Efavirenz (Sustiva) + Empagliflozin (Jardiance) Transporter induction

    Efavirenz (Sustiva) inducer of P-gp may alter Empagliflozin (Jardiance) absorption / distribution

  • moderate
    Fisetin + Empagliflozin (Jardiance) Transporter inhibition

    Fisetin inhibitor of BCRP may alter Empagliflozin (Jardiance) absorption / distribution

  • moderate
    Ginkgo Biloba (EGb 761) + Empagliflozin (Jardiance) Transporter inhibition

    Ginkgo Biloba (EGb 761) inhibitor of P-gp may alter Empagliflozin (Jardiance) absorption / distribution

Serum checks 27 modeled interaction pairings for empagliflozin (jardiance) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME trial) Zinman B et al. · New England Journal of Medicine, 2015 DOI

    Practice-changing RCT (7020 patients) demonstrating empagliflozin reduced cardiovascular death by 38%, heart failure hospitalization by 35%, and all-cause mortality by 32% in T2D with established CVD.

  2. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved) Anker SD et al. · New England Journal of Medicine, 2021 DOI

    Landmark RCT establishing empagliflozin as the first drug to show benefit in HFpEF, reducing the composite of CV death or HF hospitalization by 21%, regardless of diabetes status.

2 published studies referenced in the app, each with a plain-language summary.